Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 23, 2026
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Journal: Nature communications
Published: February 06, 2026
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 21, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
Journal: medRxiv : the preprint server for health sciences
Published: October 17, 2024
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Journal: Prostate cancer and prostatic diseases
Published: July 31, 2023
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Journal: Gynecologic oncology
Published: October 26, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 01, 2022
Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report.
Journal: Gynecologic oncology reports
Published: October 18, 2021
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Journal: Molecular cancer therapeutics
Published: March 25, 2021
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.
Journal: JCO precision oncology
Published: August 12, 2020
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 09, 2020
Last Updated: 09/26/2026